Ionis Pharmaceuticals Inc. (NASDAQ:IONS) went down by -2.12% from its latest closing price compared to the recent 1-year high of $66.22. The company’s stock price has collected -3.81% of loss in the last five trading sessions. Press Release reported 7 hours ago that Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA
Is It Worth Investing in Ionis Pharmaceuticals Inc. (NASDAQ :IONS) Right Now?
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) scored a price-to-earnings ratio above its average ratio, recording 52.90 x from its present earnings ratio. Plus, the 36-month beta value for IONS is at 1.46. Opinions of the stock are interesting as 9 analysts out of 23 who provided ratings for Ionis Pharmaceuticals Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 9 rated it as “hold,” and 4 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $67.70, which is $20.5 above the current price. IONS currently public float of 56.58M and currently shorts hold a 13.97% ratio of that float. Today, the average trading volume of IONS was 764.01K shares.
IONS’s Market Performance
IONS stocks went down by -3.81% for the week, with a monthly drop of -12.94% and a quarterly performance of -21.18%, while its annual performance rate touched -16.96%. The volatility ratio for the week stands at 3.24% while the volatility levels for the past 30 days are set at 3.16% for Ionis Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -8.38% for IONS stocks with a simple moving average of -15.36% for the last 200 days.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with JP Morgan repeating the rating for IONS by listing it as a “Neutral.” The predicted price for IONS in the upcoming period, according to JP Morgan is $63 based on the research report published on September 14th of the current year 2020.
IONS Trading at -12.43% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.34% of loss for the given period.
Volatility was left at 3.16%, however, over the last 30 days, the volatility rate increased by 3.24%, as shares sank -12.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.28% lower at present.
During the last 5 trading sessions, IONS fell by -3.81%, which changed the moving average for the period of 200-days by -24.74% in comparison to the 20-day moving average, which settled at $51.45. In addition, Ionis Pharmaceuticals Inc. saw -21.45% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at IONS starting from CROOKE STANLEY T, who sale 50,000 shares at the price of $50.41 back on Sep 22. After this action, CROOKE STANLEY T now owns 650,391 shares of Ionis Pharmaceuticals Inc., valued at $2,520,460 using the latest closing price.
CROOKE STANLEY T, the Exec Chairman of the Board of Ionis Pharmaceuticals Inc., sale 2,000 shares at $50.18 during a trade that took place back on Sep 21, which means that CROOKE STANLEY T is holding 1,581 shares at $100,360 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- +32.59 for the present operating margin
- +98.18 for the gross margin
The net margin for Ionis Pharmaceuticals Inc. stands at +26.42. The total capital return value is set at 16.99, while invested capital returns managed to touch 15.06. Equity return is now at value 9.40, with 4.20 for asset returns.
Based on Ionis Pharmaceuticals Inc. (IONS), the company’s capital structure generated 53.53 points at debt to equity in total, while total debt to capital is 34.87. Total debt to assets is 24.36, with long-term debt to equity ratio resting at 53.40. Finally, the long-term debt to capital ratio is 34.78.
Currently, EBITDA for the company is -47.72M with total debt to EBITDA at 2.02. When we switch over and look at the enterprise to sales, we see a ratio of 6.35, with the company’s debt to enterprise value settled at 0.11. The receivables turnover for the company is 29.62 and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.97.